day one | day two | focus day one | focus day two

Collaborations, Alliances and Partnerships DayOctober 22, 2008 Sharing real-life experiences and exploring the practicalities, problems and solutions that lead to profitable, enduring collaborations 09:00 Securing big gains from Pharma-Academia alliances Deepening your knowledge of the emerging trends in bio-therapeutics research Identifying beneficial opportunities for industry and academic collaboration Examining the differences of working with Academia vs. Biotechs – special considerations that need to be acknowledged in order to achieve a successful partnership Peter G. Ulrich, Co-Founder, President & CEO , TargeGen, Inc. 09:40 Revealing how Pharma makes partnering and licensing decisions Matching objectives to opportunities Explaining the value proposition and decision criteria Revealing core considerations within deal valuation Real-life examples to exemplify decision-making in practice Dr Frances Heller, Head of Strategic Alliances, Novartis Institutes for BioMedical Research 10:20 Networking coffee break 11:05 Partnering and licensing deal valuation panel session: Fighting against frenzied collaborations Expert opinions on what is driving deal valuations: Are the deals appropriately valued or is this panic-buying by big Pharma caused by the lack of products in the pipeline? Dr. Yael Weiss, Director, Worldwide Licensing & External Research, Merck & Co., Inc. 11:30 Virtual R&D case study; The "peer-reviewed virtuous virtual pharmaceutical company(tm)" of the 21st century Whoever owns the SNPs owns the industry; GenoMed is league-leader Learn why the 21st century pharma industry is up for grabs; SNPs identify the furthest upstream steps in pathogenesis, hence the best drug targets Understand how patentable cocktails of existing drugs can be tested in Phase IV trials immediately (hence "virtuous" pharma) Investigate peer-review; thousands of targets; and screening first for toxicity, only later for efficacy while eliminating risk for investors The virtual company can be global; any country can take over. Anybody with relatively little capital can own the pharmaceutical industry Dr. David W. Moskowitz, Chairman, Chief Executive Officer, and Chief Medical Officer, GenoMed, Inc. 12:15 Buffet lunch 13:30 Afternoon site visit: tour of Amira Pharmaceuticals Research Facility . Main tour host: Dr. Jilly Evans, Vice President, Biology, Co-Founder, Amira Pharmaceuticals

Afternoon site visit: Tour of Amira Pharmaceuticals Research Facility
Waples Research Centre, San Diego

Amira Pharmaceuticals is a small molecule biopharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease.

Amira Pharmaceuticals and GlaxoSmithKline announced in February 2008 that they had entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein) inhibitors for the treatment of respiratory and cardiovascular disease.

Under the terms of the agreement GSK will be granted an exclusive, worldwide license to develop, manufacture and commercialize Amira’s FLAP inhibitors, including AM103 and other compounds within the current development program. In the event that all potential development and regulatory milestones are successfully achieved, Amira could receive up to US $425 million in upfront and milestone payments. In addition, Amira will be entitled to receive tiered royalty payments based on worldwide net sales and commercial sales milestones.

Not only has Amira benefited from an agreement with GSK: in January 2006, Amira signed a broad agreement with Roche covering a research alliance and an option to in-license two compounds from Roche.

Please book early as places are restricted to a maximum of 30 persons only. Your place is secured on the tour only after email confirmation from the organizers

Schedule of events

13.30 Bus Departs 14:00 Short introduction to Amira Pharmaceuticals Brief introduction to Amira Pharmaceuticals and background explanation of the tour Jilly Evans, Co-Founder & Vice President, Amira Pharmaceuticals 14.10 Tour of the Amira Pharmaceutical research facility During this tour attendees will view the following research hubs within Amira: Medicinal chemistry lab Drug Metabolism and pharmacokinetics lab In vitro and in vivo biology lab 14:35 Amira Presentation: Sharing the secrets of our success - practical and pragmatic R&D principles developed in the face of a challenging drug development environment Making the link between innovative research to develop novel therapies and working productively within a collaborative R&D environment Associating the practical insights revealed in the tour with the theoretical company objectives put in place to achieve goals 15:00 Question and discussion session 15:15 Refreshments and networking 16:00 Return to conference venue